**Supplementary Table 1. The disease activity index (DAI) scores of colitis.**

|  |  |  |  |
| --- | --- | --- | --- |
| Score | Weight loss (%) | Stool consistency | Blood in feces |
|  0 | None | Firm or soft, dry stools | - or +  |
|  1 |  ≤5 | —— | —— |
|  2 |  >5 and ≤10 | Loose, moist stools | ++ or +++ |
|  3 |  >10 and ≤15 | —— | —— |
|  4 |  >15 | Watery diarrhea | ++++ or gloss bleeding  |

**Supplementary Table 2.** **Bile acids identified in this study.**

|  |  |  |  |
| --- | --- | --- | --- |
| Targeted bile acids | Abbreviations | Targeted bile acids | Abbreviations |
| Dehydrolithocholic acid | DHLCA | Allocholic acid | alloCA |
| Isoallolithocholic acid | isoalloLCA | Cholic acid | CA |
| Isolithocholic acid | isoLCA | Glycolithocholic acid | GLCA |
| Lithocholic acid | LCA | Glycoursodeoxycholicacid | GUDCA |
| 23-Nordeoxycholic acid  | 23-NDCA | Glycohyodeoxycholic acid | GHDCA |
| 7-Ketolithocholic acid | 7-KLCA | Glycodeoxycholic acid | GDCA |
| 12-Ketolithocholic acid | 12-KLCA | Glycohyocholic acid | GHCA |
| Apocholic acid | apoCA | Glycocholic acid | GCA |
| Ursodeoxycholic acid | UDCA | Taurolithocholic acid | TLCA |
| Hyodeoxycholic acid | HDCA | Tauroursodeoxycholic acid | TUDCA |
| Chenodeoxycholic acid | CDCA | Taurohyodeoxycholic acid | THDCA |
| Deoxycholic acid | DCA | Taurochenodeoxycholic acid | TCDCA |
| Isodeoxycholic acid | isoDCA | Taurodeoxycholic acid | TDCA |
| Dehydrocholic acid | DHCA | Tauro α-Muricholic acid | T-α-MCA |
| 7,12-Diketolithocholic acid | 7,12-DKLCA | Tauro β-Muricholic acid | T-β-MCA |
| 6,7-Diketolithocholic acid | 6,7-DKLCA | Taurocholic acid | TCA |
| 7-Ketodeoxycholic acid  | 7-KDCA | Hyocholic acid | HCA |
| 12-Dehydrocholic acid | 12-DHCA |
| 3-Dehydrocholic acid | 3-DHCA |
| Ursocholic acid | UCA |
| α-Muricholic acid | α-MCA |
| β-Muricholic acid | β-MCA |



**Supplementary Figure 1. Tacrolimus treatment at different dosages in DSS-induced colitis.** (A&B) Body weight changes and DAI scores of mice in different treatment groups. n=6~8 per group. (C&D) Gross view and length of colon. n=6 per group. (E) Survival rate of mice during the experiments. Data are presented as the mean ± SEM. \*\**P* < 0.01 and \*\*\*\* *P* < 0.0001. Significance reported in (D) and (E) is for comparison of the DSS+10Tacro and DSS groups. Con: control; DSS: dextran sulfate sodium; 0.1Tacro: 0.1 mg/kg tacrolimus; 1Tacro: 1 mg/kg tacrolimus; 10Tacro: 10 mg/kg tacrolimus.



**Supplementary Figure 2. *Lactobacillus* levels in samples from West China Hospital.** (A) Correlation analysis between *Lactobacillus* relative abundance and DAI score. A total of 17 samples from the Con, DSS and DSS+Tacro groups were included in this analysis. (B) *Lactobacillus* abundance in log 2 scale among different treatment groups. Data are presented as the mean ± SEM. DAI: disease activity index. Con: control; DSS: dextran sulfate sodium; Tacro: 10 mg/kg tacrolimus.



**Supplementary Figure 3. The profile of infiltrating immune cells among the Con, DSS, DSS + Tacro and DSS + Tacro + Lacto groups.** Data are presented as the mean ± SEM. \* *P* < 0.05. Con: control; DSS: dextran sulfate sodium; Tacro: 10 mg/kg tacrolimus; Lacto: *Lactobacillus plantarum* 550. n=3 per group.